Evidence map›Paper›PMID 31050734›Full record

ArticleInflammatory bowel diseases2019

Changes in Vedolizumab Utilization Across US Academic Centers and Community Practice Are Associated With Improved Effectiveness and Disease Outcomes.

Jenna L Koliani-Pace, Siddharth Singh, Michelle Luo, Robert Hirten, Satimai Aniwan, Gursimran Kochhar, Shannon Chang, Dana Lukin, Youran Gao, Matthew Bohm and 25 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Inflammatory bowel diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Can we change the natural course of inflammatory bowel disease?Therapeutic advances in gastroenterology · 2023
    Review
  5. Observational
  6. Head-to-head trials in inflammatory bowel disease: past, present and future.Nature reviews. Gastroenterology & hepatology · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

35 authors.

Jenna L Koliani-PaceDartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Siddharth SinghUniversity of California, San Diego, La Jolla, California, USA.
Michelle LuoTakeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Robert HirtenIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Satimai AniwanChulalongkorn University, King Chulalongkorn Memorial Hospital, Thai Red Cross Society, Bangkok, Thailand.
Gursimran KochharCleveland Clinic Foundation, Cleveland, Ohio, USA.
Shannon ChangNew York University, New York, New York, USA.
Dana LukinMontefiore Medical Center, New York, New York, USA.
Youran GaoNorth Shore University Hospital, Manhasset, New York, USA.
Matthew BohmIndiana University, Indianapolis, Indiana, USA.
Arun SwaminathLenox Hill Hospital, New York, New York, USA.
Nitin GuptaUniversity of Minnesota, Minneapolis, Minnesota, USA.
Eugenia ShmidtUniversity of Mississippi, Jackson, Mississippi, USA.
Joseph MeserveUniversity of California, San Diego, La Jolla, California, USA.
Adam WintersIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Shreya ChablaneyIcahn School of Medicine at Mount Sinai, New York, New York, USA.
David M FaleckIcahn School of Medicine at Mount Sinai, New York, New York, USA.
Jiao YangTakeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Zhongwen HuangTakeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Brigid S BolandUniversity of California, San Diego, La Jolla, California, USA.
Preeti ShashiCleveland Clinic Foundation, Cleveland, Ohio, USA.
Aaron WeissNew York University, New York, New York, USA.
David HudesmanUniversity of California, San Diego, La Jolla, California, USA.
Sashidhar VarmaIndiana University, Indianapolis, Indiana, USA.
Monika FischerIndiana University, Indianapolis, Indiana, USA.
Keith SultanNorth Shore University Hospital, Manhasset, New York, USA.
Bo ShenCleveland Clinic Foundation, Cleveland, Ohio, USA.
Sunanda KaneMayo Clinic, Rochester, Minnesota, USA.
Edward V LoftusMayo Clinic, Rochester, Minnesota, USA.
Bruce E SandsMayo Clinic, Rochester, Minnesota, USA.
Jean-Frederic ColombelMayo Clinic, Rochester, Minnesota, USA.
William J SandbornUniversity of California, San Diego, La Jolla, California, USA.
Karen LaschTakeda Pharmaceuticals U.S.A., Inc., Deerfield, Illinois, USA.
Corey A SiegelDartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Parambir S DulaiUniversity of California, San Diego, La Jolla, California, USA.

Funding

Comparative Risks and Benefits of Pharmacological Therapies for Older Patients with Inflammatory Bowel DiseasesK23DK117058 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SINGH, SIDDHARTH · 2018 to 2022
$971k
NIDDK NIH HHS K23 DK117058
6 · The paper itself

Abstract

backgroundVedolizumab effectiveness estimates immediately after Food and Drug Administration (FDA) approval for ulcerative colitis (UC) and Crohn's disease (CD) are limited by use in refractory populations. We aimed to compare treatment patterns and outcomes of vedolizumab in 2 time frames after FDA approval.

methodsWe used 2 data sets for time trend analysis, an academic multicenter vedolizumab consortium (VICTORY) and the Truven MarketScan database, and 2 time periods, May 2014-June 2015 (Era 1) and July 2015-June 2017 (Era 2). VICTORY cumulative 12-month clinical remission, corticosteroid-free remission, and mucosal healing rates, and Truven 12-month hospitalization and surgery rates, were compared between Eras 1 and 2 using time-to-event analyses.

resultsA total of 3661 vedolizumab-treated patients were included (n = 1087 VICTORY, n = 2574 Truven). In both cohorts, CD and UC patients treated during Era 2 were more likely to be biologic naïve. Compared with Era 1, Era 2 CD patients in the VICTORY consortium had higher rates of clinical remission (31% vs 40%, P = 0.03) and mucosal healing (42% vs 58%, P < 0.01). These trends were not observed for UC. In the Truven database, UC patients treated during Era 2 had lower rates of inflammatory bowel disease-related hospitalization (22.4% vs 9.6%, P < 0.001) and surgery (17.2% vs 9.4%, P = 0.008), which was not observed for CD.

conclusionSince FDA approval, remission and mucosal healing rates have increased for vedolizumab-treated CD patients, and vedolizumab-treated UC patients have had fewer hospitalizations and surgeries. This is likely due to differences between patient populations treated immediately after drug approval and those treated later.

Indexed as

AdultAntibodies, Monoclonal, HumanizedColitis, UlcerativeCrohn DiseaseDatabases, FactualFemaleGastrointestinal AgentsHospitalizationHumansMaleMiddle AgedRemission InductionRetrospective StudiesSurgical Procedures, OperativeUnited StatesWound HealingAntibodies, Monoclonal, HumanizedGastrointestinal Agentsvedolizumabhospitalizationsurgerytrends utilizationvedolizumab

Identifiers

PMID31050734
PMCPMC6799947

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.